Trials / Active Not Recruiting
Active Not RecruitingNCT07142161
A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allo-CD7 CAR-T Cells in T1DM
A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allogeneic CD7-targeted CAR-T Cell Injection in the Treatment of Type 1 Diabetes
- Status
- Active Not Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 3 (estimated)
- Sponsor
- Nanjing Bioheng Biotech Co., Ltd. · Industry
- Sex
- All
- Age
- 1 Year – 60 Years
- Healthy volunteers
- Not accepted
Summary
This is an open clinical pharmacological translational Research Study, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RD13-02 in patients with aT1DM
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RD13-02 cell infusion | CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphami |
Timeline
- Start date
- 2025-07-20
- Primary completion
- 2026-07-24
- Completion
- 2026-12-25
- First posted
- 2025-08-26
- Last updated
- 2025-08-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07142161. Inclusion in this directory is not an endorsement.